Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.
Next-generation sequencing (NGS) enables researchers and drug developers to better understand the biology that drives cancer predisposition. These insights have led to the development of targeted therapeutics and the era of ‘personalized medicine’.
BGI offers a wide variety of comprehensive genomic solutions to leading pharmaceutical providers across the world.